Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch
C A Sheridan
Topics & Concepts
Duchenne muscular dystrophyDrugOligonucleotideConjugateModality (human–computer interaction)MedicineComputational biologyDrug discoveryTreatment modalityBioinformaticsPharmacologyMuscular dystrophyExon skippingPrecision medicineTargeted drug deliveryComputer scienceDrug developmentAntibody-drug conjugateMutationDrug industryMuscle Physiology and DisordersGenetic Neurodegenerative DiseasesCardiomyopathy and Myosin Studies